X

Trial Profile

A Phase I/IB Study of Avelumab in Combination With Gemcitabine for Advanced Renal Cell Carcinoma With Sarcomatoid Differentiation

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Gemcitabine (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions

Most Recent Events

23 Aug 2022 Status changed from recruiting to discontinued due to protracted accrual and limited patient engagement in thesetting of rapidly changing treatment paradigms for advanced RCC with sarcomatoid features and/or intermediate/poor risk clinical features.
22 Jul 2021 Planned End Date changed from 19 Mar 2022 to 1 Jul 2024.
22 Jul 2021 Planned primary completion date changed from 19 Mar 2021 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com